Integral Diagnostics Ltd
IDX: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|r%v^nh | LOCK|Gg | LOCK|@^>V^<? |
Integral: Trading Update Broadly In Line With Our Expectations
No-moat Integral’s first-quarter fiscal 2024 Australian revenue grew 8.4% on the previous corresponding period, or PCP, versus market growth of 9.5%. We slightly trim our group revenue forecasts by 2% on average over the next 10 years but this is largely offset by the time value of money and lower forecast capital expenditure and depreciation expense. Our EBIT forecasts are broadly unchanged, and we maintain our AUD 3.60 fair value estimate with shares remaining undervalued.
